Esperion Therapeutics (ESPR) Competitors $2.39 -0.02 (-0.83%) (As of 09:46 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ESPR vs. RDUS, OMER, CARA, PAHC, CALT, HRMY, IRON, EVO, TARS, and GLPGShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Radius Recycling (RDUS), Omeros (OMER), Cara Therapeutics (CARA), Phibro Animal Health (PAHC), Calliditas Therapeutics AB (publ) (CALT), Harmony Biosciences (HRMY), Disc Medicine (IRON), Evotec (EVO), Tarsus Pharmaceuticals (TARS), and Galapagos (GLPG). Esperion Therapeutics vs. Radius Recycling Omeros Cara Therapeutics Phibro Animal Health Calliditas Therapeutics AB (publ) Harmony Biosciences Disc Medicine Evotec Tarsus Pharmaceuticals Galapagos Radius Recycling (NASDAQ:RDUS) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap business services companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings. Do insiders & institutionals have more ownership in RDUS or ESPR? 78.1% of Radius Recycling shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 5.7% of Radius Recycling shares are held by company insiders. Comparatively, 1.0% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer RDUS or ESPR? Esperion Therapeutics received 271 more outperform votes than Radius Recycling when rated by MarketBeat users. Likewise, 69.89% of users gave Esperion Therapeutics an outperform vote while only 53.50% of users gave Radius Recycling an outperform vote. CompanyUnderperformOutperformRadius RecyclingOutperform Votes34453.50% Underperform Votes29946.50% Esperion TherapeuticsOutperform Votes61569.89% Underperform Votes26530.11% Which has more volatility and risk, RDUS or ESPR? Radius Recycling has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Is RDUS or ESPR more profitable? Radius Recycling has a net margin of -9.73% compared to Esperion Therapeutics' net margin of -29.37%. Esperion Therapeutics' return on equity of 0.00% beat Radius Recycling's return on equity.Company Net Margins Return on Equity Return on Assets Radius Recycling-9.73% -9.83% -4.66% Esperion Therapeutics -29.37%N/A -10.77% Does the media refer more to RDUS or ESPR? In the previous week, Esperion Therapeutics had 6 more articles in the media than Radius Recycling. MarketBeat recorded 7 mentions for Esperion Therapeutics and 1 mentions for Radius Recycling. Esperion Therapeutics' average media sentiment score of 0.36 beat Radius Recycling's score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radius Recycling 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Esperion Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer RDUS or ESPR? Esperion Therapeutics has a consensus target price of $8.17, indicating a potential upside of 241.70%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than Radius Recycling.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Radius Recycling 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Esperion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has preferable earnings & valuation, RDUS or ESPR? Esperion Therapeutics has lower revenue, but higher earnings than Radius Recycling. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Radius Recycling, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRadius Recycling$2.74B0.19-$266.41M-$9.36-2.00Esperion Therapeutics$116.33M4.05-$209.25M-$0.64-3.73 SummaryEsperion Therapeutics beats Radius Recycling on 11 of the 18 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$470.93M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-3.734.9789.5613.60Price / Sales4.05371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book-1.2710.306.976.33Net Income-$209.25M$153.61M$119.04M$225.93M7 Day Performance13.81%-1.73%-1.78%-0.96%1 Month Performance16.02%-7.26%-3.59%1.06%1 Year Performance100.84%31.10%31.64%26.59% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics3.9536 of 5 stars$2.39-0.8%$8.17+241.7%+97.5%$470.93M$116.33M-3.73240Analyst ForecastRDUSRadius Recycling2.1412 of 5 stars$18.70+1.3%N/A-27.2%$524.35M$2.74B-1.973,011OMEROmeros3.6864 of 5 stars$6.03flat$9.00+49.3%+244.6%$349.44MN/A-2.61198Analyst UpgradeCARACara Therapeutics3.9304 of 5 stars$0.31flat$2.32+660.7%-71.2%$16.73M$20.97M0.0055Analyst ForecastPAHCPhibro Animal Health4.2299 of 5 stars$23.39-1.5%$16.50-29.5%+123.4%$947.30M$1.02B54.401,940Analyst DowngradeCALTCalliditas Therapeutics AB (publ)0.2583 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180Positive NewsHRMYHarmony Biosciences4.7919 of 5 stars$33.01+0.7%$47.00+42.4%+18.1%$1.88B$582.02M15.54200IRONDisc Medicine3.1676 of 5 stars$62.59+0.1%$85.80+37.1%+22.4%$1.86BN/A0.0078Insider TradeAnalyst RevisionEVOEvotec1.9292 of 5 stars$5.21-1.7%$5.93+13.9%-49.7%$1.85B$845.74M0.005,061TARSTarsus Pharmaceuticals1.8691 of 5 stars$46.25-0.7%$54.20+17.2%+166.2%$1.77B$17.45M-12.2350Analyst RevisionGLPGGalapagos1.2816 of 5 stars$25.47-0.7%$30.75+20.7%-31.4%$1.68B$259.40M0.001,123Analyst DowngradeShort Interest ↓News CoverageGap Down Related Companies and Tools Related Companies Radius Recycling Competitors Omeros Competitors Cara Therapeutics Competitors Phibro Animal Health Competitors Calliditas Therapeutics AB (publ) Competitors Harmony Biosciences Competitors Disc Medicine Competitors Evotec Competitors Tarsus Pharmaceuticals Competitors Galapagos Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ESPR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESPR Stock Alerts